Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer

Autor: Roubaud, Guilhem, Attard, Gerhardt, Boegemann, Martin, Olmos, David, Trevisan, Marco, Antoni, Laurent, Pascoe, Katie, Capone, Camille, Van Sanden, Suzy, Hashim, Mahmoud, Palmer, Stephen, Chi, Kim
Zdroj: In European Journal of Cancer September 2024 209
Databáze: ScienceDirect
Externí odkaz: